Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer

• Type of Material: Article
• Authors: Nicholas Scott-Wittenborn, Johns Hopkins University; Gypsyamber D'Souza, Johns Hopkins University; Nafi Aygun, Johns Hopkins Univ Hosp; Sakshi R Tewari, Johns Hopkins University; Javad Azadi, Johns Hopkins Univ Hosp; Peter Vosler, Johns Hopkins University; Zhen Gooi, University of Chicago; Vikas Mehta, Montefiore Medical Center; Wojciech Mydlarz, Johns Hopkins University; Meloine Nance, University of Pittsburgh; Stefan Mlot, ENT and Allergy Associates LLP; Mihir Patel, Emory University; Marietta Tan, Johns Hopkins University; Brett A Miles, Northwell Health; Tanya Troy, Johns Hopkins University; Carole Fakhry, Johns Hopkins University
• Language: English
• Date: 2022-10-06
• Publisher: WILEY
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2022 Wiley Periodicals LLC.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1002/hed.27212
• Title of Journal or Parent Work: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
• Volume: 45
• Issue: 1
• Start Page: 95
• End Page: 102
• Grant/Funding Information: 5T32DC000027-29: Dr. Scott-Wittenborn; R35DE026631: Dr. D’Souza
• Keywords: Otorhinolaryngology; MRI; HPV; PLASMA; Life Sciences & Biomedicine; INFECTION; HUMAN-PAPILLOMAVIRUS VACCINATION; HEAD; ultrasound; SQUAMOUS-CELL CARCINOMA; Surgery; Science & Technology; DNA; oropharyngeal cancer; head and neck cancer; NECK-CANCER

Abstract

Background: Human papillomavirus-associated oropharynx squamous cell carcinoma (HPV-OPSCC) has no known pre-malignant lesion. While vaccination offers future primary prevention, there is current interest in secondary prevention. The feasibility of clinical evaluation of individuals at increased risk for HPV-OPSCC is unclear. Methods: Individuals with risk factors for HPV-OPSCC were enrolled in a prospective study (MOUTH). Participants positive for biomarkers associated with HPV-OPSCC were eligible for a clinical evaluation which comprised a head and neck examination and imaging with ultrasound and/or magnetic resonance imaging (MRI). This study was designed to evaluate feasibility of clinical evaluation in a screening study. Results: Three hundred and eighty-four participants were eligible for clinical evaluation. Of the 384, 204 (53%) completed a head and neck examination or imaging. Of these, 66 (32%) completed MRI (n = 51) and/or ultrasound (n = 64) studies. Conclusions: Clinical evaluations, including head and neck examination and imaging, are feasible in the context of a screening study for HPV-OPSCC.